Provider profile · Membership plus medication
Hers review: services, costs, and questions
Hers' weight-loss care offer, separate membership and medicine costs, and product-specific safety questions.
What the official information says
The official Hers page describes a weight-loss membership and treatment options assessed by a clinician. It is part of the Hims & Hers group, but enrollment, product choices, and billing should be checked against the specific Hers offer.
A program marketed to women should still identify the exact medicine and formulation. Pregnancy, contraception, and breastfeeding need a clinician-led discussion; marketing about personalization does not replace product-specific safety labeling.
Sources: Hers weight-loss program
Pricing and the full bill
The advertised membership is $39 for the first month, automatically renewing at $149 per month, separately from medication. Confirm whether any quoted medicine price is dose-specific or requires a longer commitment, and obtain the total ongoing bill before paying.
A first-month price is not a reliable annual budget. Ask for the amount charged today, the renewal interval, the cost after any promotion, and whether medication, supplies, visits, labs, and shipping are included. Obtain cancellation and refund terms before paying, particularly if a prescription has not yet been approved.
Sources: Hers weight-loss program
Limitations that affect your decision
Approved and compounded medicines are different regulatory categories. A compounded tablet cannot inherit approved oral Wegovy evidence merely because both mention semaglutide.
Tirzepatide and Foundayo have product-specific oral contraceptive precautions. Do not assume that one safety rule covers every medicine offered through a platform.
Medication trials evaluate specific formulations, doses, and study populations. A provider advertising semaglutide or tirzepatide has not thereby demonstrated that its own treatment produces the results of Wegovy or Zepbound trials. A compounded medicine is not FDA-approved and should not be described as an approved generic equivalent.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Questions to ask before enrollment
- Which product's pregnancy and contraceptive instructions apply to my prescription?
- What are the medication and membership cancellation rules separately?
- What exact medicine, formulation, and device would I receive, and which pharmacy dispenses it?
- Who prescribes in my state, and how do I obtain urgent clinical help?
- What will I pay at maintenance, and when do renewals and cancellation deadlines occur?
Ask the prescribing clinician how your other medicines, diabetes treatment, pregnancy plans, gastrointestinal history, and follow-up needs affect eligibility. Check the dispensing pharmacy with the relevant state board. A reassuring website or testimonial does not replace those checks.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Personalization still requires a product-specific safety discussion
Hers advertises a clinician-assessed weight-loss pathway and a menu of named medications. Marketing directed to women does not replace the exact label's pregnancy, contraception, and breastfeeding instructions. Ask which product and route are being proposed, what the treatment purpose is, and which precautions apply before the first dose.
Tirzepatide requires a non-oral contraceptive method or added barrier protection for four weeks after initiation and each escalation when oral hormonal contraception is used. Foundayo uses 30 days, while semaglutide has a two-month planned-pregnancy discontinuation instruction. The periods should not be merged into one platform-wide rule. The clinician should also review other medicines and medical conditions. A personalized offer is useful only when the actual prescription and follow-up plan are clear.
Sources: Hers weight-loss program · Zepbound prescribing information · Foundayo prescribing information · Wegovy prescribing information, including tablets and Wegovy HD
Two separately billed parts create the full cost
The refreshed Hers page states that medication pricing excludes the required membership. Membership is advertised at $39 for the first month and renews automatically at $149 per month afterward. Ask whether the medication quote is for a starter or maintenance dose and which promotional or eligibility restrictions apply.
Write down both charges, the amount due today, each renewal interval, and each cancellation rule. For example, if your confirmed pharmacy quote were $299, adding the advertised recurring $149 membership would make $448 before other costs. That is conditional arithmetic, not a guaranteed price for every prescription. Ask how no prescription, a clinical pause, or membership cancellation affects medication access and refunds. The first-month membership discount does not describe the continuing pharmacy bill or the total annual commitment.
Sources: Hers weight-loss program
Assess the advertised support and outcomes separately
The page describes care-team access and nutrition and exercise guidance. Ask how those services work in the selected plan: which contact is clinical, how dose changes are reviewed, and whether an in-person assessment or coordination with another clinician is needed. We have not tested response times or care continuity.
A provider's reference to a Wegovy trial describes the manufactured medicine studied, not proof that every Hers patient has the same result. If an alternative compounded preparation is offered, it cannot borrow the approved tablet's absorption, label, or outcomes. Confirm the pharmacy and product on the actual prescription and review the administration routine. The decision should combine medical suitability, practical use, ongoing support, and the full bill, while keeping public advertising distinct from independently verified service performance.
Sources: Hers weight-loss program · Wegovy prescribing information, including tablets and Wegovy HD · FDA concerns with unapproved GLP-1 drugs used for weight loss · NIDDK: choosing a safe and successful weight-loss program
Sources and evidence
Provider sources support advertised services and terms. Clinical and regulatory sources explain medication and pharmacy considerations. These are distinct kinds of evidence.
- Hers weight-loss program
- Zepbound prescribing information
- Foundayo prescribing information
- Wegovy prescribing information, including tablets and Wegovy HD
- FDA concerns with unapproved GLP-1 drugs used for weight loss
- NIDDK: choosing a safe and successful weight-loss program
- FDA clarification of compounding policies as GLP-1 supply stabilizes